(Reuters) - Chimerix Inc said its experimental drug failed to show significant benefit in a mid-stage study involving a type of viral infection that mainly affects the lungs. The drug, brincidofovir, was being tested on 48 patients with blood and bone marrow cancers who had adenovirus infection (AdV), a potentially fatal condition which has no known approved treatments. The trial was designed to evaluate the potential to decrease the viral infection or prevent its progression. The drug was given to patients once or twice a week. ... via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment